Pre-admission anticoagulant therapy and mortality in hospitalized COVID-19 patients: A retrospective cohort study. Issue 208 (December 2021)

• Record Type: Journal Article
• Authors: van Haaps, Thijs F.; Collard, Didier; van Osch, Frits H.M.; Middeldorp, Saskia; Coppens, Michiel; de Kruif, Martijn D.; Vlot, Eline A.; Douma, Renée A.; ten Cate, Hugo; Juffermans, Nicole P.; Gritters, Niels; Vlaar, Alexander P.; Reidinga, Auke C.; Heuvelmans, Marjolein A.; Oudkerk, Matthijs; Büller, Harry R.; van den Bergh, Joop P.W.; Maas, Arno; Ten Wolde, Marije; Simsek, Suat; Beudel, Martijn; van Es, Nick
• Is Part Of: Thrombosis research. Issue 208(2021)
• Page Start: 35
• Page End: 38
• Publication Date: 2021-12
• Subjects: COVID-19 -- Thrombosis -- Anticoagulants -- SARS-CoV-2 -- Mortality; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2021.10.006
• Languages: English
• ISSNs: 0049-3848

Abstract

Highlights: Hypercoagulability is a hallmark of COVID-19 patients. It is unknown if pre-admission anticoagulant improves patient outcomes. We studied 380 anticoagulant users and 380 matched controls with COVID-19. Pre-admission anticoagulation was not associated with mortality and ICU admission.